79 related articles for article (PubMed ID: 2495640)
1. Prophylactic use of OKT3 in cardiac transplantation.
Konertz W; Weyand M; Friedl A
Transplant Proc; 1989 Feb; 21(1 Pt 3):2494-6. PubMed ID: 2495640
[No Abstract] [Full Text] [Related]
2. OKT3 delays rejection crises after heart transplantation.
Weimar W; Essed CE; Balk AH; Simoons ML; Hendriks GF; Wenting GJ; Mochtar B; Bos E
Transplant Proc; 1989 Feb; 21(1 Pt 3):2497-8. PubMed ID: 2495641
[No Abstract] [Full Text] [Related]
3. Prophylactic OKT3 in renal retransplantation.
Cardella CJ; Blake P; Cattran D; Cole E
Transplant Proc; 1989 Apr; 21(2):3373-4. PubMed ID: 2496509
[No Abstract] [Full Text] [Related]
4. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic OKT3 used as induction therapy for heart transplantation.
Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
[TBL] [Abstract][Full Text] [Related]
6. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection.
Gilbert EM; Eiswirth CC; Renlund DG; Menlove RL; DeWitt CW; Freedman LA; Herrick CM; Gay WA; Bristow MR
Transplant Proc; 1987 Apr; 19(2 Suppl 1):45-53. PubMed ID: 3105140
[No Abstract] [Full Text] [Related]
7. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization.
Moore CK; O'Connell JB; Renlund DG; Bristow MR; Hammond EH
Transplant Proc; 1991 Feb; 23(1 Pt 2):1055-8. PubMed ID: 1899151
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
9. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
Hegewald MG; O'Connell JB; Renlund DG; Lee HR; Burton NA; Karwande SV; Jones KW; Lassetter JE; Bristow MR
J Heart Transplant; 1989; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
[TBL] [Abstract][Full Text] [Related]
10. Selective use of OKT3 in heart transplantation with the use of risk factor analysis.
Macris MP; Van Buren CT; Sweeney MS; Frazier OH; Duncan JM
J Heart Transplant; 1989; 8(4):296-302. PubMed ID: 2504896
[TBL] [Abstract][Full Text] [Related]
11. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
Kremer AB; Barnes L; Hirsch RL; Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
[No Abstract] [Full Text] [Related]
12. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
13. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
14. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
[TBL] [Abstract][Full Text] [Related]
15. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First MR
Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
[No Abstract] [Full Text] [Related]
16. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
17. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients.
Ippoliti G; Negri M; Abelli P; Rovati B; Di Franco L; Grossi P; Minoli L; Ascari E; Viganó M
Transplant Proc; 1991 Aug; 23(4):2272-4. PubMed ID: 1908155
[No Abstract] [Full Text] [Related]
18. The prophylactic use of Orthoclone OKT3 in kidney and heart transplantation.
Weimar W; Baumgartner D; Hendriks GF; Hesse CJ; Balk AH; Simoons ML; Bos E
Transplant Proc; 1988 Oct; 20(5 Suppl 6):96-100. PubMed ID: 3140455
[No Abstract] [Full Text] [Related]
19. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
Campos A; Lage E; Hinojosa R; Ordóñez A; Cisneros JM; Cabezón S; Gómez S; Aguilera A; Arana E; Cayuela A
Transplant Proc; 2005 Apr; 37(3):1548-9. PubMed ID: 15866669
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody OKT3 in cardiac and renal transplantation.
Norman DJ
Bibl Cardiol; 1988; (43):27-32. PubMed ID: 3147656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
